Mikkel Dybkjaer

CFO at Hoba Therapeutics - N/A, N/A, DK

Mikkel Dybkjaer's Colleagues at Hoba Therapeutics
Gordon Munro

VP Preclinical Development

Contact Gordon Munro

Anna-Kathrine Pedersen

Industrial Postdoc at Hoba Therapeutics Aps and Novo Nordisk Foundation Center for protein Research

Contact Anna-Kathrine Pedersen

John Kemp

Chief Scientific Officer

Contact John Kemp

Mikkel Dybkjaer's Contact Details
HQ
N/A
Location
Copenhagen,Capital Region of Denmark,Denmark
Company
Hoba Therapeutics
Mikkel Dybkjaer's Company Details
Hoba Therapeutics logo, Hoba Therapeutics contact details

Hoba Therapeutics

N/A, N/A, DK • 5 - 9 Employees
BioTech/Drugs

Hoba Therapeutics was established November 2016 and funded by Novo Seeds and Borean Innovation. The company is developing biopharmaceuticals for the treatment of pain and CNS disorders. Our pipeline includes two patented endogenous neurotrophic factors with shared properties. The lead compound is HB-086 (human recombinant Meteorin) and preclinical studies support therapeutic use in neuropathy and associated neuropathic pain. HB-097 (human recombinant Cometin) is in early preclinical development for hearing disorders. Our mission is to provide innovative effective, safe and disease modifying treatments to patients living with neuropathic pain

N/A
Details about Hoba Therapeutics
Frequently Asked Questions about Mikkel Dybkjaer
Mikkel Dybkjaer currently works for Hoba Therapeutics.
Mikkel Dybkjaer's role at Hoba Therapeutics is CFO.
Mikkel Dybkjaer's email address is ***@hobatherapeutics.com. To view Mikkel Dybkjaer's full email address, please signup to ConnectPlex.
Mikkel Dybkjaer works in the Research industry.
Mikkel Dybkjaer's colleagues at Hoba Therapeutics are Gordon Munro, Kenneth Petersen, Anna-Kathrine Pedersen, Torsten Madsen, John Kemp and others.
Mikkel Dybkjaer's phone number is N/A
See more information about Mikkel Dybkjaer